Pharmaceutical firms increasingly face significant and complex challenges, particularly with pharmaceutical design simulations and in modeling biological systems. Designing accurate simulations to predict drug behavior requires extreme computational power and increasingly sophisticated algorithms. Creating biological models to test drug interactions requires replicating intricate biological environments, a task made more complex by innovative new treatment methods. Navigating both of these challenges are pivotal to the industry, as inaccuracies can delay development, increase costs, and pose potential risks during the length and costly clinical trial cycle.